Gilberto Lopes

3.2k total citations · 1 hit paper
108 papers, 1.9k citations indexed

About

Gilberto Lopes is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Gilberto Lopes has authored 108 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Oncology, 52 papers in Pulmonary and Respiratory Medicine and 20 papers in Economics and Econometrics. Recurrent topics in Gilberto Lopes's work include Lung Cancer Treatments and Mutations (26 papers), Cancer Immunotherapy and Biomarkers (18 papers) and Economic and Financial Impacts of Cancer (18 papers). Gilberto Lopes is often cited by papers focused on Lung Cancer Treatments and Mutations (26 papers), Cancer Immunotherapy and Biomarkers (18 papers) and Economic and Financial Impacts of Cancer (18 papers). Gilberto Lopes collaborates with scholars based in United States, Brazil and United Kingdom. Gilberto Lopes's co-authors include Bijou R. Hunt, Clement Adebamowo, Jonas A. de Souza, Fredrick Chite Asirwa, Yi‐Long Wu, Gilberto de Castro, Debra Kush, Bilal Piperdi, Tony Mok and Giuseppe Curigliano and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Gilberto Lopes

97 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

2022 144 citations Gilberto Lopes et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gilberto Lopes United States	21	1.2k	874	284	259	205	108	1.9k
Norbert Marschner Germany	25	1.3k 1.1×	649 0.7×	349 1.2×	407 1.6×	258 1.3×	153	2.2k
Josephine Feliciano United States	24	1.5k 1.2×	941 1.1×	139 0.5×	173 0.7×	261 1.3×	104	2.1k
Athanasios Pallis Greece	31	1.5k 1.2×	1.1k 1.3×	369 1.3×	401 1.5×	265 1.3×	103	2.7k
Alan P. Lyss United States	27	1.2k 1.0×	879 1.0×	327 1.2×	374 1.4×	323 1.6×	66	2.7k
Julien Péron France	28	1.0k 0.8×	453 0.5×	240 0.8×	207 0.8×	363 1.8×	121	2.1k
Monique M.E.M. Bos Netherlands	19	1.1k 0.9×	667 0.8×	407 1.4×	527 2.0×	203 1.0×	36	2.1k
Oscar Bertetto Italy	26	1.2k 1.0×	639 0.7×	207 0.7×	318 1.2×	561 2.7×	105	2.3k
Jane Bryce Italy	19	978 0.8×	408 0.5×	151 0.5×	355 1.4×	175 0.9×	41	1.8k
Alice Nennecke Germany	14	1.2k 1.0×	521 0.6×	203 0.7×	198 0.8×	358 1.7×	36	2.0k
Aakash Desai United States	23	797 0.7×	380 0.4×	186 0.7×	355 1.4×	137 0.7×	139	1.9k

Countries citing papers authored by Gilberto Lopes

Since Specialization

Citations

This map shows the geographic impact of Gilberto Lopes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gilberto Lopes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gilberto Lopes more than expected).

Fields of papers citing papers by Gilberto Lopes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gilberto Lopes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gilberto Lopes. The network helps show where Gilberto Lopes may publish in the future.

Co-authorship network of co-authors of Gilberto Lopes

This figure shows the co-authorship network connecting the top 25 collaborators of Gilberto Lopes. A scholar is included among the top collaborators of Gilberto Lopes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gilberto Lopes. Gilberto Lopes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Menezes, Cláudia Beatriz Afonso de, et al.. (2025). Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis. The Oncologist. 30(2). 3 indexed citations

Jani, Chinmay, Ana S. Salazar, Justin D. Salciccioli, et al.. (2025). Evolving trends in lung cancer risk factors in the ten most populous countries: an analysis of data from the 2019 Global Burden of Disease Study. EClinicalMedicine. 79. 103033–103033. 8 indexed citations

Trabolsi, Asaad, Andrew Elliott, Estelamari Rodríguez, et al.. (2024). The Genomic, Transcriptomic, and Immunologic Landscape of HRAS Mutations in Solid Tumors. Cancers. 16(8). 1572–1572. 1 indexed citations

Brown, Clyde, et al.. (2024). Racial/ethnic disparities in curative‐intent treatment for early‐stage non‐small cell lung cancer patients among heterogeneous Black populations: US‐born Black, Afro‐Haitian, West Indian Black, and Hispanic Black. Cancer Medicine. 13(19). e7449–e7449. 2 indexed citations

Aziz, Zeba, et al.. (2024). ASCO Global Guidelines: Methods and Opportunities. JCO Global Oncology. 10(10). e2400310–e2400310.

Lopes, Gilberto, et al.. (2022). Diagnóstico de câncer de mama e COVID-19: uma análise de incidência nos estados da Bahia e Rio Grande do Norte. Research Society and Development. 11(2). e59611226283–e59611226283. 1 indexed citations

Lopes, Gilberto, et al.. (2021). Bayo Lapawol (Let Their Voices Be Heard): Haitian Women’s Barriers to and Facilitators of Cervical Cancer Prevention and Control. Health Education & Behavior. 48(6). 873–884. 6 indexed citations

Tsimberidou, Apostolia M., Dejan Juric, Claire F. Verschraegen, et al.. (2021). Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer. Journal of Hematology & Oncology. 14(1). 127–127. 20 indexed citations

Remón, Jordi & Gilberto Lopes. (2020). Upfront osimertinib — winner takes it all?. Nature Reviews Clinical Oncology. 17(4). 202–203. 7 indexed citations

10.

Saul, Michelle, et al.. (2020). The challenges of implementing low-dose computed tomography for lung cancer screening in low- and middle-income countries. Nature Cancer. 1(12). 1140–1152. 37 indexed citations

11.

Aguiar, Pedro Nazareth, et al.. (2019). In the Era of Cost-Effectiveness Analysis, Affordability Is a Limiting Factor for Patients' Access to Innovative Cancer Treatments. Value in Health Regional Issues. 20. 47–50. 15 indexed citations

12.

Arrossi, Silvina, Sarah Temin, Suzanne M. Garland, et al.. (2017). Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline. Journal of Global Oncology. 3(5). 611–634. 30 indexed citations

13.

Aguiar, Pedro Nazareth, et al.. (2017). OA17.01 Estimate of Economic Impact of Immune Checkpoint Inhibitors for NSCLC Relative to PD-L1 Expression in the US. Journal of Thoracic Oncology. 12(1). S308–S308. 1 indexed citations

14.

Wilking, Nils, et al.. (2017). Can we Continue to Afford Access to Cancer Treatment?. European Oncology & Haematology. 13(2). 114–114. 14 indexed citations

15.

Aguiar, Pedro Nazareth, Ramon Andrade de Mello, Hakaru Tadokoro, Hani M. Babiker, & Gilberto Lopes. (2017). MA14.11 An Estimate of the Economic Impact of Immunotherapy Relative to PD-L1 Expression in Brazil - An Update with Brazilian Costs. Journal of Thoracic Oncology. 12(1). S427–S427. 1 indexed citations

16.

Lopes, Gilberto. (2016). P1.41 (also presented as PD2.06): Bayesian Network Meta-Comparison of Maintenance Treatments for Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients. Journal of Thoracic Oncology. 11(10). S207–S208. 1 indexed citations

17.

Aguiar, Pedro Nazareth, et al.. (2016). P2.45: An Estimate of the Economic Impact of Treatment of NSCLC With Immunotherapy Relative to PD-L1 Expression in Brazil. Journal of Thoracic Oncology. 11(10). S246–S246. 1 indexed citations

18.

Soares, Heloisa P., Soley Bayraktar, Marcelo Blaya, et al.. (2014). A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Cancer Chemotherapy and Pharmacology. 73(4). 839–845. 8 indexed citations

19.

Bastos, Bruno R., Georges F. Hatoum, Gail Walker, et al.. (2010). Efficacy and Toxicity of Chemoradiotherapy with Carboplatin and Irinotecan Followed by Consolidation Docetaxel for Unresectable Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(4). 533–539. 15 indexed citations

20.

Raez, Luis E., Edgardo S. Santos, Gilberto Lopes, et al.. (2006). Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). Lung Cancer. 53(3). 347–353. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact